Genprex, Inc.

We are a clinical stage gene therapy company focused on developing gene-based therapies for large patient populations with unmet medical needs. Our oncology platform uses our systemic, non-viral ONCOPREX® Delivery System, which employs lipid-based nanoparticles in a lipoplex form to deliver tumor suppressor gene-expressing plasmids to cancer cells. This product is administered intravenously and is taken up by tumor cells, which then express tumor suppressor proteins that were deficient in the tumor. Our diabetes technology for Type 1 diabetes aims to transform alpha cells in the pancreas into functional beta-like cells capable of producing insulin, potentially distinct enough from beta cells to evade the immune system. For Type 2 diabetes, our technology is believed to replenish and rejuvenate exhausted insulin-producing beta cells. Our lead oncology drug candidate, REQORSA® Gene Therapy (quaratusugene ozeplasmid), formerly GPX-001, is being developed in combination with approved cancer drugs to treat Non-Small Cell Lung Cancer (NSCLC) and Small Cell Lung Cancer (SCLC). REQORSA has multimodal effects on cancer cells, harming their metabolism and reducing growth. Its mechanism of action decreases tumor glucose metabolism, interrupts cell signaling pathways causing cancer cell replication and proliferation, re-establishes programmed cell death (apoptosis) in cancer cells, and increases the immune response against them. Preclinical studies indicate REQORSA is complementary with targeted drugs and immunotherapies. Our strategy is to develop REQORSA in combination with currently approved therapies for NSCLC, SCLC, and potentially other cancers.